Brief report · 28 Nov 2025
Review articlePublished 2017
Reduction of Hepatotoxicity Induced by Doxorubicin
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Doxorubicin (DOX) has been used in the treatment of variety of cancers but its administration is limited by a dosedependent toxicity. Its cytotoxic effects on malignant cells have shown an increase in the risk of cardiotoxicity, hepatoxicity, renal insufisance. Antioxydants have been explored for both their cancer preventive properties and chemodulatory of DOX toxicity. Resveratrol (RSV) is a polyphenolic constituent of several dietary mainly of grapes and wine origin recently its anticancer potential has been extensively explored, revealing its anti-proliferative effect on different cancer cell lines, both in vitro and in vivo. RSV is also known to have modulatory effects on cell apoptosis, migration and growth via various signaling pathways. Though, RSV possesses great medicinal value, its applications as a therapeutic drug is limited. Problems like low oral bioavailability and poor aqueous solubility make RSV an unreliable candidate for therapeutic purposes. Additionally, the rapid gastrointestinal digestion of RSV is also a major barrier for its clinical translation. Hence, to overcome these disadvantages RSV-based nanodelivery systems have been considered in recent times. Nanodelivery systems of RSV have shown promising results in its uptake by the epithelial system as well as enhanced delivery to the target site. Herein we have tried to bring new new insights into the molecular mechanisms of DOX toxicity with respect to DNA damage, free radicals and whether RSV can be a playmaker as chemodulatory of DOx.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Integrative Oncology.
Brief report · 28 Nov 2025
Biomarkers Predict Integrative Oncology Treatment Response
Opinion · 28 Nov 2025
Navigating Integrative Oncology Trial Design: Innovation and Ethics
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Integrative Oncology
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Dorsaf Bengaied”
- BylineArticles whose byline prints “Antonio Ribeiro”
- BylineArticles whose byline prints “Mohamed Amri”
- BylineArticles whose byline prints “Daniel Scherman”
- BylineArticles whose byline prints “Philippe Arnaud”
